These innovative molecules represent a significant leap in the management of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in lowering blood glucose levels. https://diegovddg406735.sharebyblog.com/39000637/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide